Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thats it but im just a bit sceptical because they are at exploration stage. Its too early to say if there will be something or not in their region. But i like that they habe reduced OS over the years fron the 10Q
i have just read the presentation from their homepage. they look to explore gold in Columbia, Santa Cruz region. this stock could be worth 10-20 times more than now.
http://www.sagoldcorp.com/v1/
nice continuation. has anyone made already some DD on this one? cheers.
bummer glad i removed my bid. not so friendly here!!!! NOT AT ALL
i think i rather go fishing, than watching this at the moment. :):)
woohooo A/S 1 Billion.
subscribed.
lets see...
this is gonna end up below a penny, question just when and if they are gonna pump it too 3.00$ before.
nice here from friday! like this stock.
ohh nice stock here.
hey Board ,what do we have here.
super low floater alert. uh oh!
Nice continuation from friday.
Never gonnna tell my buys again :).
on watch
this one looks nice adding to watch.
bought some at a 0.00255$ avarage. not much shares but got some. like the trading so far here and looking for news.
out of a little bump became a awesome upwards trend. we closed above the 200dma today.
subscribed* kinda late to the party, well see.
nice close!
nice upward movement now with bid support.
lol personmarked you. Yummmmi Peanuts. :)
the OTC Markets page says he bought 31.5Mil at 0.001 and sold 1.9Mil at 0.0016$, has anyone did some research on the CEO, fraud etc..? "Melvin W. Coles"
Shares
Bought
31,467,500
Sold
1,862,000
http://www.otcmarkets.com/stock/HPCS/insider-transactions
adding this on watch, nice share structure lets see if there more is coming. do not like the business though but there is people who may buy this stuff. this could see 0.035-0.04$ with the right story.
unfortunately i have no position, good job.
what happend here back in May? the stock crashed down big time..
whats up punk.
1.53$
ARNA 6.58$ Chart:
MINYANVILLE ORIGINAL In a stunning turn of events in less than two years, diet pill maker Arena Pharmaceuticals (ARNA) won the backing of a panel of government advisers to sell what may be the first new weight-loss treatment in the US in more than a decade. The company’s shares rose 80% in early trading Friday after advisers voted 18-4 in favor of approving Arena’s drug, lorcaserin.
Arena is the second company to win such an endorsement for a diet drug this year after Vivus (VVUS) was recommended by Food and Drug Administration advisers in February. The FDA delayed a decision on Vivus’ Qnexa, moving a potential approval date later than one set for Arena. If the FDA doesn’t adjust its dates, it will decide on Arena’s drug, lorcaserin, by June 27, and on Vivus’ Qnexa by July 17.
After a pair of overwhelmingly positive panel recommendations from advisers, it’s beginning to look like there may be two near-term approvals for diet drugs. That seemed unthinkable a little more than a year ago after Orexigen Therapeutics (OREX) followed Arena and Vivus in being rejected by the US agency because of safety concerns.
Shares of Arena rose to $6.59 in morning trading. Vivus was up 4% to $23.57 and Orexigen, which is the farthest away from any potential approval, jumped 7% to $3.57.
Safety has been the killer for these new diet pills. The FDA is very cautious about approving another product that could pose health risks to people taking them. Abbott Laboratories (ABT) withdrew its drug Meridia from the market in 2010 after fears of heart attack and stroke. The drug cocktail fen phen was withdrawn from the market in 1997 after evidence of heart valve damage. Those drugs were sold by American Home Products, which was later renamed Wyeth and is now part of Pfizer (PFE).
In April, Vivus said the FDA was extending its deadline for an approval ruling on Qnexa because the agency needed more time to review a company plan on mitigating risks for patients. Arena, which is partnered with Japanese drug maker Eisai to sell lorcaserin, has responded to FDA worries about safety, including heart valve problems. However, Arena hasn’t yet discussed a risk plan -- a so-called a risk evaluation and mitigation strategy -- or a post-approval safety study with the FDA, company executives said on a conference call Friday. Eisai would pay 90% of any post-approval safety analysis. No decision has been made yet on a price for the pill.
Arena, Vivus and Orexigen argue that obesity is an epidemic in the US, leading to health problems such as heart disease, diabetes and other conditions
Read more: http://www.minyanville.com/sectors/biotech-pharma/articles/arena-pharmaceuticals-lorcaserin-jack-lief-diet/5/11/2012/id/40949#ixzz1uwWYj9UL
great move up here, last time i saw this was under 0.50$ a share.